Equity Overview
Price & Market Data
Price: $0.0999
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $13,805,884
Daily Volume: 0
Performance Metrics
1 Week: 11.00%
1 Month: 7.42%
3 Months: 98.41%
6 Months: 108.8%
1 Year: 81.64%
YTD: 113.0%
Company Details
Employees: 8
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.